Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis

Bibliographic Details
Title: Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis
Authors: David Hakimian, Johnny Amer, Alaa Jammal, Asher Shafrir, Yael Milgrom, Mohammad Masarowah, Wadi Hazou, Yuval Ishay, Ashraf Imam, Adi Francis, Abed Khalaileh, Rifaat Safadi
Source: Vaccine: X, Vol 15, Iss , Pp 100359- (2023)
Publisher Information: Elsevier, 2023.
Publication Year: 2023
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: Pfizer's mRNA SARS-CoV-2 vaccine, Serum SARS-CoV-2 spike immunoglobulins, NAS score, Liver fibrosis stage, Fibroscan, Immunologic diseases. Allergy, RC581-607
More Details: Background: SARS-CoV-2 vaccine responses that could harbor potential risks to chronic liver diseased patients. Aims: To assess immune response following Pfizer's SARS-CoV-2 vaccine in patients with different liver fibrosis severities of nonalcoholic fatty liver disease (NAFLD). Methods: Clinical and histological (NAS-score and fibrosis stage) characteristics of NAFLD patients before vaccine were correlated with serologic vaccine responses of two doses of the BNT162b2. Serum SARS-CoV-2 spike immunoglobulins (anti-S) were assessed on day seven following immunization (Liaison assay). Results: The mean-age of patients (n = 157) was 56.9 ± 13.2 years (46.5 % males). 94.8 % had a positive response (anti-S levels ≥ 19 AU/ml). The anti-S cutoff of 200 AU/ml used to separate strong vs. weak responses. A strong response (anti-S titers ≥ 200 AU/ml) was observed in 93/157 (59.2 %) patients with a mean-age of 53.1 ± 13.8 years (45.2 % males). A weak response (anti-S titers
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2590-1362
Relation: http://www.sciencedirect.com/science/article/pii/S2590136223001006; https://doaj.org/toc/2590-1362
DOI: 10.1016/j.jvacx.2023.100359
Access URL: https://doaj.org/article/af4b55d4ed4142b8ae2d7851c624af9a
Accession Number: edsdoj.f4b55d4ed4142b8ae2d7851c624af9a
Database: Directory of Open Access Journals
More Details
ISSN:25901362
DOI:10.1016/j.jvacx.2023.100359
Published in:Vaccine: X
Language:English